Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Dosificación de antibióticos pediátricos en oxigenación por membrana extracorpórea (PADECMO) (PADECMO)

16 de septiembre de 2026 actualizado por: University Hospital, Ghent

Dosificación de antibióticos pediátricos en oxigenación por membrana extracorpórea

Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).

Descripción general del estudio

Descripción detallada

The study will investigate whether - with the current dosing regimens of meropenem, piperacillin-tazobactam, amoxicillin-clavulanate, cephazolin, vancomycin, amikacin, teicoplanin and ciprofloxacin - pharmacodynamic targets are attained in a national multicentric clinical setting in pediatric patients on ECMO.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

300

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Pieter De Cock, PharmD
  • Número de teléfono: +32 9 332 29 69
  • Correo electrónico: pieter.decock@uzgent.be

Ubicaciones de estudio

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

No mayor que 15 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • patients admitted to the pediatric intensive care unit or cardiac intensive care unit
  • patient age : 1,8 kg-15 years
  • patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)
  • intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)
  • extracorporeal membrane oxygenation circuit

Exclusion Criteria:

  • no catheter in place for blood sampling
  • absence of parental/patient consent
  • known hypersensitivity to beta-lactam antibiotics and ciprofloxacin

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: Amoxicillin-clavulanate

Patients receiving amoxicillin-clavulanate as part of routine clinical care. Study procedure: blood sampling

blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care

Otros nombres:
  • Muestra de sangre
Otro: Piperacillin-tazobactam

Patients receiving piperacillin-tazobactam as part of routine clinical care. Study procedure: blood sampling

blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.

Otros nombres:
  • Muestra de sangre
Otro: Meropenem

Patients receiving meropenem as part of routine clinical care. Study procedure: blood sampling

blood sampling in patients receiving meropenem as part of routine clinical care.

Otros nombres:
  • Muestra de sangre
Otro: Cefazolin

Patients receiving cefazolin as part of routine clinical care. Study procedure: blood sampling

blood sampling in patients receiving cefazolin as part of routine clinical care.

Otros nombres:
  • Muestra de sangre
Otro: Vancomycin

Patients receiving vancomycin as part of routine clinical care. Study procedure: blood sampling

blood sampling in patients receiving vancomycin as part of routine clinical care.

Otros nombres:
  • Muestra de sangre
Otro: Teicoplanin

Patients receiving teicoplanin as part of routine clinical care. Study procedure: blood sampling

blood sampling in patients receiving teicoplanin as part of routine clinical care.

Otros nombres:
  • Muestra de sangre
Otro: Ciprofloxacin

Patients receiving ciprofloxacin as part of routine clinical care. Study procedure: blood sampling

blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.

Otros nombres:
  • Muestra de sangre
Otro: Amikacin

Patients receiving amikacin as part of routine clinical care. Study procedure: blood sampling

blood sampling in patients receiving amikacin as part of routine clinical care.

Otros nombres:
  • Muestra de sangre

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Amoxicillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Periodo de tiempo: up to 1 month

% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Periodo de tiempo: up to 1 month

% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Periodo de tiempo: up to 1 month

% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Periodo de tiempo: up to 1 month

% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Amoxicillin, piperacillin, meropenem, cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Periodo de tiempo: up to 1 month

% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Periodo de tiempo: up to 1 month

% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Periodo de tiempo: up to 1 month

% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Periodo de tiempo: up to 1 month

% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Periodo de tiempo: up to 1 month

% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen off extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Periodo de tiempo: up to 1 month

% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Periodo de tiempo: up to 1 month

% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
for teicoplanin: probability of target attainment with the target being an Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration Ratio (AUC/MIC)
Periodo de tiempo: up to 1 month

% of patients in whom an AUC/MIC of 900 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
for amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Periodo de tiempo: up to 1 month

% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Periodo de tiempo: up to 1 month

% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Periodo de tiempo: up to 1 month

% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions

up to 1 month
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Periodo de tiempo: July 2026

% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions

July 2026
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Periodo de tiempo: July 2026

% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions

July 2026

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Risk factors for underdosing during extracorporeal membrane oxygenation for beta-lactam antibiotics
Periodo de tiempo: up to 1 month

The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a percentage of time during which the unbound concentration remains above the Minimal Inhibitory Concentration (MIC) of the micro-organism of at least 50% and a maximum concentration of 10 x MIC

up to 1 month
Risk factors for underdosing during extracorporeal membrane oxygenation for ciprofloxacin
Periodo de tiempo: up to 1 month

The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of ciprofloxacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 86

up to 1 month
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for vancomycin
Periodo de tiempo: up to 1 month

The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of vancomycin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 200 to 300

up to 1 month
Risk factors for underdosing during extracorporeal membrane oxygenation for teicoplanin
Periodo de tiempo: up to 1 month

The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of teicoplanin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is an Area-under the concentration-Time Curve of 900

up to 1 month
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for amikacin
Periodo de tiempo: up to 1 month

The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of amikacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a peak over Minimal Inhibitory Concentration Ratio of 8 to 10, trough concentration below 5 mg/L and Area under the Concentration Time Curve/MIC>399

up to 1 month
Beta-lactam antibiotics (amoxicillin, piperacillin, meropenem, cefazolin): probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC)
Periodo de tiempo: up to 1 month

% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in first dose conditions

up to 1 month
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Periodo de tiempo: up to 1 month

% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions

up to 1 month
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Periodo de tiempo: up to 1 month

% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions

up to 1 month
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Periodo de tiempo: up to 1 month

% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions

up to 1 month
Amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Periodo de tiempo: up to 1 month

% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions

up to 1 month
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Periodo de tiempo: up to 1 month

% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions

up to 1 month

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Annick de Jaeger, MD, University Hospital, Ghent

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de agosto de 2016

Finalización primaria (Estimado)

1 de julio de 2029

Finalización del estudio (Estimado)

1 de julio de 2029

Fechas de registro del estudio

Enviado por primera vez

13 de mayo de 2022

Primero enviado que cumplió con los criterios de control de calidad

17 de mayo de 2024

Publicado por primera vez (Actual)

23 de mayo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

21 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir